Login / Signup

Anti-viral immunity in the tumor microenvironment: implications for the rational design of herpes simplex virus type 1 oncolytic virotherapy.

Paul J F RiderIfeanyi K UcheLarissa SweenyKonstantin G Kousoulas
Published in: Current clinical microbiology reports (2019)
It is not entirely clear how the immunosuppressive tumor microenvironment affects oncolytic viral replication and spread within tumors. Recent work has shown that the manipulation of specific cellular and molecular mechanisms of immunosuppression operating within the tumor microenvironment can enhance the efficacy of oncolytic virotherapy. We anticipate that future work will integrate greater knowledge of immunosuppression in tumor microenvironments with design of oncolytic virotherapies.
Keyphrases
  • herpes simplex virus
  • sars cov
  • healthcare
  • current status